Conversely, the anti-RANKL pre-treatment group showed an aggravation compared to the CLP group, suggesting that recombinant RANKL enhances the signaling of RANK, thereby alleviating the inflammatory response and kidney function damage of SA-AKI. The gene discussed is TNFSF11; the disease is acute kidney injury.